Heather Getz Purchases 15,000 Shares of TELA Bio (NASDAQ:TELA) Stock

TELA Bio, Inc. (NASDAQ:TELA) CEO Heather Getz bought 15,000 shares of the company’s stock in a transaction dated Friday, August 14th. The stock was purchased at an average cost of $0.70 per share, for a total transaction of $10,500.00. Following the completion of the acquisition, the chief executive officer owned 520,000 shares in the company, valued at $364,000. This trade represents a 2.97% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

TELA Bio Stock Performance

NASDAQ TELA traded up $0.01 during trading on Monday, reaching $0.65. 241,010 shares of the company’s stock were exchanged, compared to its average volume of 166,260. The business has a 50 day moving average price of $0.78 and a 200-day moving average price of $0.80. The stock has a market capitalization of $29.18 million, a P/E ratio of -0.84 and a beta of 1.34. The company has a debt-to-equity ratio of 8.82, a current ratio of 2.99 and a quick ratio of 2.38. TELA Bio, Inc. has a fifty-two week low of $0.50 and a fifty-two week high of $2.00.

TELA Bio (NASDAQ:TELA) last released its quarterly earnings data on Monday, August 10th. The company reported ($0.20) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.17) by ($0.03). TELA Bio had a negative net margin of 51.53% and a negative return on equity of 1,320.81%. The business had revenue of $19.29 million during the quarter, compared to the consensus estimate of $20.01 million. Sell-side analysts forecast that TELA Bio, Inc. will post -0.76 earnings per share for the current fiscal year.

Analyst Ratings Changes

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of TELA Bio in a report on Friday, July 17th. Three investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $2.20.

Institutional Investors Weigh In On TELA Bio

Institutional investors have recently made changes to their positions in the stock. Perkins Capital Management Inc. increased its stake in TELA Bio by 1.5% during the 1st quarter. Perkins Capital Management Inc. now owns 1,418,328 shares of the company’s stock worth $879,000 after acquiring an additional 20,910 shares during the period. Citadel Advisors LLC raised its holdings in TELA Bio by 161.3% in the 3rd quarter. Citadel Advisors LLC now owns 35,281 shares of the company’s stock valued at $53,000 after acquiring an additional 21,781 shares in the last quarter. XTX Topco Ltd bought a new stake in shares of TELA Bio during the 4th quarter valued at $48,000. Renaissance Technologies LLC lifted its position in shares of TELA Bio by 101.4% during the 4th quarter. Renaissance Technologies LLC now owns 128,700 shares of the company’s stock valued at $152,000 after acquiring an additional 64,800 shares during the period. Finally, Susquehanna International Group LLP lifted its position in shares of TELA Bio by 551.2% during the 3rd quarter. Susquehanna International Group LLP now owns 85,763 shares of the company’s stock valued at $128,000 after acquiring an additional 72,594 shares during the period. 94.35% of the stock is currently owned by institutional investors.

About TELA Bio

TELA Bio, Inc (NASDAQ: TELA) is a commercial‐stage medical technology company headquartered in Malvern, Pennsylvania. The company is focused on developing, manufacturing and commercializing regenerative medicine and advanced soft tissue repair solutions. By integrating proprietary biomaterials and processing technologies, TELA Bio aims to offer products that support the body’s natural healing processes in wound closure, hernia repair, reconstructive surgery and other surgical specialties.

The company’s product portfolio includes acellular dermal matrices, hemostatic agents and tissue scaffold systems.